CVS Health study highlights GLP-1 benefits and the affordability challenge

ملخص مفصل

CVS Health today released new research grounded in real-world data that puts numbers behind a central question facing employers and health plans as GLP-1 use grows: Do the medicines save enough elsewhere in the health care system to offset their cost?

Real-world analysis finds better outcomes and lower medical spending, but current prices limit the full economic value

WOONSOCKET, R.I., Nov. 15, 2026 /PRNewswire/ -- CVS Health today released new research grounded in real-world data that puts numbers behind a central question facing employers and health plans as GLP-1 use grows: Do the medicines save enough elsewhere in the health care system to offset their cost?

Using anonymized Aetna claims data from commercial fully insured members, CVS Health researchers found GLP-1 use was associated with better clinical outcomes, lower hospital use and lower medical spending compared with matched non-users. At current prices, those medical savings did not fully offset increased pharmacy spending.

"GLP-1s are remarkably effective medicines, and the health benefits are real. The challenge is making those benefits affordable at scale," said Amy Compton-Phillips, M.D. "That means getting treatment to the people most likely to benefit, helping them stay on therapy and bringing the price to a level that supports broader access."

The study examined commercial fully insured Aetna members who used GLP-1s, with index years from 2023 through 2025 and up to three years of follow-up. Researchers matched GLP-1 users with similar non-users based on factors including age, existing health conditions, prior health care use and medical and pharmacy spending.

Modeling from this study suggests that, across the study population, a net price of approximately $350 per month over three years would bring pharmacy spending and observed medical savings into balance. The break-even point varies based on factors including patients' underlying clinical risk, how long they remain on treatment and how consistently they take their medication.

Researchers also examined whether staying on treatment mattered, comparing all people who started a GLP-1 with those whose prescriptions covered at least 80% of days during follow-up, a standard measure of medication…

The…

The…

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.